Seattle Genetics Highlights Updated Progression-Free Survival and Overall Survival Data from ADCETRIS (Brentuximab …

Seattle Genetics, Inc. today highlighted ADCETRIS data to be presented at the 2014 European Society for Medical Oncology Congress being held September 26-30, 2014 in Madrid, Spain.

Here is the original post:
Seattle Genetics Highlights Updated Progression-Free Survival and Overall Survival Data from ADCETRIS (Brentuximab …

Cell-Fuel Announces Launch of Products and New Website

NEW YORK, Sept. 30, 2014 /PRNewswire-iReach/ — Cell-Fuel, LLC has officially announced the launch of their new website and product line. The revolutionary supplement program, called Cell-Fuel, has been …

Read the original post:
Cell-Fuel Announces Launch of Products and New Website

Athersys to Present at 2014 Stem Cell Meeting on the Mesa

CLEVELAND — Athersys, Inc. announced today that Gil Van Bokkelen, Chairman and CEO will present at the 4th Annual Partnering Forum, part of the Stem Cell Meeting on the Mesa to be held October 7-9 in …

Go here to read the rest:
Athersys to Present at 2014 Stem Cell Meeting on the Mesa

ReproCELL Launches Cell Innovation Partners, L.P. with Shinsei Bank, Limited

ReproCELL announced that it has commenced operation of Cell Innovation Partners, L.P. at the size of about USD 8.0 million, as of September 2

Continue reading here:
ReproCELL Launches Cell Innovation Partners, L.P. with Shinsei Bank, Limited

China tests stem cell therapy for heart disease – Video



China tests stem cell therapy for heart disease
Monday marks World Heart Day. One of the most serious conditions is Chronic Heart Disease. It has no cure to date, but in China, scientists are hoping to find one, using stem-cell technology.

By: CCTV America

View post:
China tests stem cell therapy for heart disease – Video

Cell therapy – Institute of Cell Therapy – …

About cell therapy

Cell therapy is a new official direction in medicine, based on the use of regenerative potential of the adult stem cells, aimed at the treatment of a variety of serious diseases, rehabilitation of patients after injuries and fighting with the premature signs of aging. Stem cells are also considered to be the promising biological material for the creation of the prosthetic heart valves, blood vessels, trachea, they are also used as the unique biofiller for the reconstitution of bone defects and other purposes of the plastic and reconstructive surgery.

The scientists explain the regenerative mechanism of action of stem cells both by their ability to transform into the cells of blood, liver, myocardium, bone, cartilage or nervous tissue and thus restore damaged organs and also by the reovery of the functional activity of the other cells (through the so-called paracrine type) by means of the production of a variety of growth factors.

For clinical purposes, in most cases stem cells are obtained from the bone marrow and cord blood, it is also known that the amount of stem cells, sufficient for treatment, can be isolated from the peripheral blood of an adult person, but after pre-stimulation of hematopoiesis. In recent years there is an increasing number of reports worldwide on the clinical application of stem cells, derived from the placenta, adipose tissue, umbilical cord tissue, amniotic fluid, and even pulp of the milk teeth. Depending on the disease, age and condition of the patient, one or another source of stem cells may be preferred. Hematopoietic (blood-forming) stem cells are used for more than 50 years in the treatment of leukemia and lymphomas, and this treatment is commonly known as the bone marrow transplantation, but today hematopoietic stem cells, derived from umbilical cord blood and peripheral blood are more often used in the hematologic clinics of the world. At the same time, for the treatment of traumatic brain and spinal cord injuries, the stimulation of fractures and chronic wounds healing the mesenchymal stem cells are more preferred, being the precursors of the connective tissue. Mesenchymal stem cells are found in big quantity in fatty tissue, placenta, umbilical cord blood, amniotic fluid. Due to the immunosuppressive effects of mesenchymal stem cells, they are also used in the treatment of a variety of autoimmune diseases (multiple sclerosis, ulcerative colitis, Crohns disease, etc.), as well as post-transplantation complications (to prevent the rejection of the transplanted donor organ). For the treatment of cardiovascular diseases, including lower limbs ischemia, the umbilical cord blood is considered to be the most promising, as it contains a special kind of the endothelial progenitor stem cells, which can not be found in any other human tissue.

Cell therapy may be autologous (own cells are used) and allogeneic (donor cells are used). However, it is known that every nucleated cell in the human body has certain immunological characteristics (HLA-phenotype or immune passport), that is why the use of donor stem cells requires immunological compatibility. This fact determines the appropriateness of the banking of the own stem cells, frozen until the person is still young and healthy. In this aspect the human umbilical cord blood has undisputed medical and biological value as the source of several unique lines of stem cells. Collected in the first minutes of life, umbilical cord blood stem cells have the highest potential for proliferation (growth) and directed differentiation.

Stem cell therapy can be applied both intravenously like a drug, and directly into the damaged tissue. In recent years the method of intraosseous transplantation of cord blood stem cells is more widely used, contributing to the more rapid engraftment. Also a method of introducing stem cells directly into the coronary arteries (coronary heart disease, myocardial infarction) was introduced and it is called cellular cardiomyoplasty.

Cell therapy can be carried out both in monotherapy and complementary to the surgical or drug treatment.

Currently stem cells are successfully used in the treatment of about 100 serious diseases, and in some cases this is the only effective treatment.

See the original post:
Cell therapy – Institute of Cell Therapy – …

Tokyo Electron Launches its Open Innovation Stem Cell Technology Centre (STC) in the UK to Develop Smart Cell …

Tokyo Electron Limited opened, through its European subsidiary Tokyo Electron Europe Limited , the companys open innovation centre at Stevenage Bioscience Catalyst in the United Kingdom.

More:
Tokyo Electron Launches its Open Innovation Stem Cell Technology Centre (STC) in the UK to Develop Smart Cell …

Cesca Therapeutics Reports Fourth Quarter and Full Fiscal 2014 Results

RANCHO CORDOVA, Calif. — Cesca Therapeutics Inc. , an autologous cell-based regenerative medicine company, today reported financial results for the fourth quarter and year-ended fiscal 2014.

More:
Cesca Therapeutics Reports Fourth Quarter and Full Fiscal 2014 Results

Cesca Therapeutics Announces Approval of Its AXP(R) AutoXpress(R) System in Taiwan

RANCHO CORDOVA, Calif. — Cesca Therapeutics Inc. , an autologous cell-based regenerative medicine company, today announced that the Company has received approval from the Taiwan Food and Drug Administration …

Read this article:
Cesca Therapeutics Announces Approval of Its AXP(R) AutoXpress(R) System in Taiwan

Advanced Cell Technology Announces Final Patient Treated in Stargardts Macular Degeneration Phase 1 Trial in the …

Advanced Cell Technology, Inc. , a leader in the field of regenerative ophthalmology, announced today that it has completed treatment of the final patient in its U.K.

See the original post here:
Advanced Cell Technology Announces Final Patient Treated in Stargardts Macular Degeneration Phase 1 Trial in the …